Discovery and Translational Research
Driving Innovation from Lab to Clinic
At Stanford Hematology, our Discovery and Translational Research program drives innovation from the lab to the clinic. We focus on understanding the biology of blood disorders and translating these insights into new therapies, diagnostic tools, and approaches that improve patient outcomes. Our team combines cutting-edge science with clinical expertise to accelerate breakthroughs in leukemia, lymphoma, myeloma, and other hematologic diseases.
Our Research Labs
Artandi Lab
In the Artandi Lab, we use sophisticated biochemical, cell biological and genomic approaches to understand the fundamental causes of these diseases. Our goal is to develop new therapeutic approaches to tackle these often intractable disease states.
Asiri Lab
Dr. Ediriwickrema currently leads a systems hematology laboratory that integrates advanced single-cell technologies, computational biology, and functional hematology to study both normal and malignant blood development.
Bhatt Lab
Dr. Ami Bhatt's lab studies how the microbiome influences patient health, especially in cancer. Using molecular biology, microbiology, and bioinformatics, the team analyzes patient biospecimens to identify microbial biomarkers and their impact on disease and treatment response. They also explore microbiome genome plasticity and investigate safe strategies, like fecal microbiota transplantation and prebiotics, to improve patient outcomes. Through interdisciplinary work, the lab aims to translate these insights into diagnostics and therapies that enhance oncology care.
Kuo Lab
Dr. Calvin Kuo's research focuses on three transformative areas: organoids, which model complex diseases like cancer for targeted treatment discovery; stem cells, investigating intestinal regeneration to advance regenerative therapies; and vascular biology, exploring brain blood vessels to develop vessel-targeted treatments for strokes and tumors. Together, these efforts aim to expand scientific understanding and drive innovative medical solutions.
Lu Lab
The Lu laboratory focuses on dissecting RNA processing in the context of hematologic disorders. The goal is to achieve an improved understanding of aberrant RNA metabolism in the service of novel therapeutics for challenging blood diseases.
Majeti Lab
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML).The major areas of focus for the lab are the investigation of pre-leukemic/clonal hematopoiesis hematopoietic stem cells, heterogeneity in AML at the single cell and stem cell level, and development of cancer immunotherapies.
Mullally Lab
The Mullally Laboratory studies myeloid blood cancers, focusing on myeloproliferative neoplasms (MPN). Using genomics, CRISPR, single-cell technologies, mouse models, and cellular biology, the lab investigates MPN biology to develop better treatments. Key areas of interest include early MPN pathogenesis, clonal hematopoiesis, MPN stem cells, bone marrow fibrosis, and the development of genetic and cellular therapies.
Zhang Lab
Dr. Zhang's clinical expertise lies in treating myeloid-derived hematologic malignancies, especially acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), clonal hematopoiesis, and therapy-related myeloid neoplasms. In essence, Dr. Zhang’s work spans a seamless integration of clinical hematology, immunology, metabolism, molecular diagnostics, and translational trial development—all centered around improving outcomes for patients with myeloid malignancies.
